1.5599
price up icon0.04%   0.0099
 
loading
Nucana Plc Adr stock is traded at $1.5599, with a volume of 24,444. It is up +0.04% in the last 24 hours and down -21.69% over the past month. NuCana PLC is a biopharmaceutical company focused on improving treatment outcomes for cancer patients by ProTide technology. Utilizing proprietary ProTide technology, the firm is developing new medicines designed to overcome key cancer resistance mechanisms and generate much higher concentrations of anti-cancer metabolites in cancer cells. The company's ProTide pipeline products are NUC-3373, NUC-7738, Acelarin. Geographically operates through the region of the United States.
See More
Previous Close:
$1.55
Open:
$1.58
24h Volume:
24,444
Relative Volume:
0.02
Market Cap:
$3.54M
Revenue:
-
Net Income/Loss:
$-33.44M
P/E Ratio:
-2.0677
EPS:
-0.7544
Net Cash Flow:
$-28.30M
1W Performance:
-11.39%
1M Performance:
-21.69%
6M Performance:
-61.23%
1Y Performance:
-86.80%
1-Day Range:
Value
$1.555
$1.60
1-Week Range:
Value
$1.53
$1.77
52-Week Range:
Value
$1.53
$19.41

Nucana Plc Adr Stock (NCNA) Company Profile

Name
Name
Nucana Plc Adr
Name
Phone
-
Name
Address
-
Name
Employee
28
Name
Twitter
@NuCana_news
Name
Next Earnings Date
2024-11-14
Name
Latest SEC Filings
Name
NCNA's Discussions on Twitter

Nucana Plc Adr Stock (NCNA) Upgrades & Downgrades

Date Action Analyst Rating Change
Mar-03-22 Downgrade Cowen Outperform → Market Perform
Oct-22-20 Initiated Truist Buy
Jul-24-20 Initiated Oppenheimer Outperform
Aug-19-19 Initiated H.C. Wainwright Buy
Oct-19-18 Initiated Piper Jaffray Overweight
Oct-23-17 Initiated Citigroup Buy
Oct-23-17 Initiated Jefferies Buy
Oct-23-17 Initiated William Blair Outperform
View All

Nucana Plc Adr Stock (NCNA) Latest News

pulisher
Sep 30, 2024

Trading Day Triumph: NuCana plc ADR (NCNA) Ends at 2.45, a -10.91 Surge/Plunge - The Dwinnex

Sep 30, 2024
pulisher
Sep 27, 2024

Get in on NuCana plc ADR’s (NCNA) buy-in window today! - SETE News

Sep 27, 2024
pulisher
Sep 26, 2024

NuCana plc ADR Inc. (NCNA) Price Performance: The Role of Share Buybacks and Stock Splits - The InvestChronicle

Sep 26, 2024
pulisher
Sep 26, 2024

NCNA’s price-to-sales ratio: Is it a good investment opportunity? - US Post News

Sep 26, 2024
pulisher
Sep 26, 2024

NuCana secures new US patent for cancer treatment NUC-7738 - Investing.com India

Sep 26, 2024
pulisher
Sep 26, 2024

Market Watch: NuCana plc ADR (NCNA)’s Noteworthy Drop, Closing at 3.05 - The Dwinnex

Sep 26, 2024
pulisher
Sep 19, 2024

Daily Market Movement: NuCana plc ADR (NCNA) Sees a -7.03 Decrease, Closing at 3.44 - The Dwinnex

Sep 19, 2024
pulisher
Sep 18, 2024

William Blair downgrades NuCana plc ADR (NCNA) rating to a Mkt perform - Knox Daily

Sep 18, 2024
pulisher
Sep 18, 2024

There is no doubt that NuCana plc ADR (NCNA) ticks all the boxes. - SETE News

Sep 18, 2024
pulisher
Sep 17, 2024

Wolfspeed Inc [WOLF] Investment Appeal on the Rise - Knox Daily

Sep 17, 2024
pulisher
Sep 17, 2024

Labcorp Holdings Inc. (LH) may enjoy gains as insiders got busy in the recent days - Knox Daily

Sep 17, 2024
pulisher
Sep 17, 2024

NuCana Stock Soars 151% on Upbeat Efficacy Data From Melanoma Study - Yahoo Finance

Sep 17, 2024
pulisher
Sep 16, 2024

NCNA’s Financial Health: Exploring NuCana plc ADR’s Debt-to-Equity Ratio of 1.79 - The InvestChronicle

Sep 16, 2024
pulisher
Sep 16, 2024

Analyzing NCNA’s price-to-book ratio for the last quarter - US Post News

Sep 16, 2024
pulisher
Sep 16, 2024

Dow Jumps Over 200 Points; NY Empire State Manufacturing Index Increases In September - Benzinga

Sep 16, 2024
pulisher
Sep 12, 2024

Endava PLC Sponsored ADR (DAVA) Expected to Beat Earnings Estimates: Can the Stock Move Higher? - Yahoo Finance

Sep 12, 2024
pulisher
Sep 12, 2024

Opera Limited Sponsored ADR (OPRA) Crossed Above the 20-Day Moving Average: What That Means for Investors - Yahoo Finance

Sep 12, 2024
pulisher
Sep 11, 2024

Did Jim Cramer Say Buy Arm Holdings PLC – ADR (NASDAQ:ARM) Industrial Stock Before Rate Cuts? - Yahoo Finance

Sep 11, 2024
pulisher
Sep 03, 2024

NuCana price target lowered to $25 from $150 at Oppenheimer - TipRanks

Sep 03, 2024
pulisher
Sep 02, 2024

In the Green: NuCana plc ADR (NCNA) Closes at 3.66, Up/Down -52.65 from Previous Day - The Dwinnex

Sep 02, 2024
pulisher
Aug 30, 2024

NuCana stock downgraded by William Blair after halted cancer study - Investing.com India

Aug 30, 2024
pulisher
Aug 29, 2024

NuCana halts NuTide:323 study on colorectal cancer - Investing.com

Aug 29, 2024
pulisher
Aug 29, 2024

NuCana Ends Phase 2 Cancer Study, Focuses on Promising Treatments - TipRanks

Aug 29, 2024
pulisher
Aug 21, 2024

Check out these key findings about NuCana plc ADR (NCNA) - SETE News

Aug 21, 2024
pulisher
Aug 20, 2024

NCNA’s Stock Market Odyssey: A Year of Growth, Decline, and Resilience - The InvestChronicle

Aug 20, 2024
pulisher
Aug 15, 2024

NuCana Reports Second Quarter 2024 Financial Results and Provides Business Update - GlobeNewswire Inc.

Aug 15, 2024
pulisher
Aug 15, 2024

NuCana Reports Second Quarter 2024 Financial Results and Provides Business Update - The Bakersfield Californian

Aug 15, 2024
pulisher
Jul 22, 2024

NuCana shares receive $150 stock PT at Oppenheimer on upbeat trial prospects - Investing.com

Jul 22, 2024
pulisher
Jul 16, 2024

Sea Limited Sponsored ADR (SE) Stock Declines While Market Improves: Some Information for Investors - Yahoo Finance

Jul 16, 2024
pulisher
Jul 12, 2024

XPeng Inc. Sponsored ADR (XPEV) Outpaces Stock Market Gains: What You Should Know - Yahoo Finance

Jul 12, 2024
pulisher
Jul 05, 2024

Co-Diagnostics (CODX) to Post Q2 Earnings: What's in Store? - Yahoo Canada Shine On

Jul 05, 2024
pulisher
Jun 20, 2024

NuCana's Biliary Tract Cancer Candidate Gets Orphan Drug Tag - Yahoo Singapore News

Jun 20, 2024
pulisher
Jun 05, 2024

NuCana Stops Patient Enrollment in Pancreatic Cancer Study - Yahoo Sport Australia

Jun 05, 2024
pulisher
Jun 03, 2024

Citi Appointed as Successor Depositary Bank for Iberdrola, S.A.’s ADR Programme - Yahoo Finance

Jun 03, 2024
pulisher
Jun 02, 2024

NuCana to Participate in the 2022 Jefferies Healthcare Conference - The Globe and Mail

Jun 02, 2024
pulisher
Jun 02, 2024

NuCana to Present at the Jefferies Virtual London Healthcare Conference - The Globe and Mail

Jun 02, 2024
pulisher
May 30, 2024

Blueprint Medicines Files NDA to FDA for Pralsetinib in MTC - Yahoo Lifestyle UK

May 30, 2024
pulisher
May 16, 2024

Protagonist Therapeutics' PTG-300 Gets FDA's Orphan Drug Tag - Yahoo New Zealand News

May 16, 2024
pulisher
May 16, 2024

Analysts Estimate Endava PLC Sponsored ADR (DAVA) to Report a Decline in Earnings: What to Look Out for - Yahoo Finance

May 16, 2024
pulisher
May 11, 2024

NuCana (NCNA) Looks Good: Stock Adds 5.7% in Session - Yahoo New Zealand News

May 11, 2024
pulisher
May 09, 2024

Bears are Losing Control Over NuCana PLC Sponsored ADR (NCNA), Here's Why It's a 'Buy' Now - Yahoo Lifestyle UK

May 09, 2024
pulisher
May 08, 2024

Should You Buy NuCana (NCNA) Ahead of Earnings? - Yahoo News UK

May 08, 2024
pulisher
May 07, 2024

NuCana (NCNA) to Report Q4 Earnings: What's in the Cards? - Yahoo Movies Canada

May 07, 2024
pulisher
May 07, 2024

Should You Buy ARM Holdings (ARM) Ahead of Earnings? - Yahoo Finance

May 07, 2024
pulisher
Mar 27, 2024

NuCana plc Announces Reverse ADS Split - TipRanks

Mar 27, 2024
pulisher
Mar 19, 2024

Why Sea Limited Sponsored ADR (SE) Might be Well Poised for a Surge - Yahoo Finance

Mar 19, 2024
pulisher
Mar 18, 2024

Why Opera Limited Sponsored ADR (OPRA) Outpaced the Stock Market Today - Yahoo Finance

Mar 18, 2024
pulisher
Jan 03, 2024

NuCana: Potential Turnaround In 2024 But Risky - Seeking Alpha

Jan 03, 2024
pulisher
Oct 26, 2023

Davion Enters into Agreement with The Bank of New York Mellon for ADR Programme and $30 Million IPO Fundraise - Yahoo Finance

Oct 26, 2023
pulisher
Aug 22, 2023

MARKET DATA - The Wall Street Journal

Aug 22, 2023
pulisher
Sep 28, 2022

Down 34.6% in 4 Weeks, Here's Why You Should You Buy the Dip in NuCana PLC Sponsored ADR (NCNA) - Yahoo Finance

Sep 28, 2022

Nucana Plc Adr Stock (NCNA) Financials Data

Revenue

loading

Net Income

loading

Cash Flow

loading

EPS

loading
$20.30
price up icon 1.75%
$75.59
price down icon 0.20%
$374.10
price down icon 0.29%
$52.67
price down icon 0.85%
$207.67
price up icon 0.20%
$108.59
price up icon 0.02%
Cap:     |  Volume (24h):